

Marck Biosciences to enter Singapore, Malaysia market

Ahmedabad, Apr 16

Marck Biosciences, a leading manufacturer and marketer of sterile dosage pharma products and Blow-Fill-Seal specialist, on Thursday, announced its plan to enter the Singapore and Malaysian market.

Marck said that its manufacturing facility had received an approval from the NPCB (National Pharmaceutical Control Bureau), ministry of health, Malaysia for large volume parenterals, small volume parenterals and ophthalmics.

Marck is the only company in India to have received the NPCB approval for its small volume parenterals facility.

Marck, which has a presence in about 70 countries across the world, plans to introduce a range of small volume parenterals, including ophthalmics, irrigation solutions, injectibles and respi-

ratory solutions, and IV parenterals formulations in the large volume parenterals in Singapore and Malaysia.

Commenting on the development, Bhavesh Patel, managing director, Marck Biosciences Ltd, said, "The NPCB approval has significant implications for Marck. First, our early entry into Malaysia and Singapore opens up a large export market for our products. Second, the manufacturers of these countries can now get their brands outsourced from Marck."

"Third, since NPCB is a participant of PIC/S - The Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme - which has 36 participating authorities, including those from UK and Australia, the approval will help our registrations endeavour in other PIC/S member countries."

"With the NPCB approval

and the most modern SVP & LVP capacity at our Kheda facility, we will efficiently cater to Malaysia, Singapore and Brunei with our vast product range. A strong marketing, sales and distribution team will be put in force by our South East Asia head to accelerate the penetration planned." added Patel. The South-East Asian countries represent a total market of 588 million people and a combined GDP of \$2.2 billion.

Marck Biosciences' manufacturing facilities are certified by many international regulatory authorities, including the ANVISA from Brazil. With a globally benchmarked manufacturing facility and technically advanced formulation and development centre, Marck provides innovative product development solutions and manufactures a varied range of "difficult-to-make" dosages for top pharma

marketers in India and the world. Today, its products are marketed in over 70 countries across Latin America, Asia, Africa, Asia and Pacific Ocean countries.

Amongst India's leading manufacturer of parenterals with Blow-Fill-Seal technology, accepted worldwide as the most advanced technology for the manufacture of sterile liquid, Marck manufactures and markets the widest range of sterile dosages spanning fluid therapy, ophthalmic, respiratory, irrigation solutions and anti-infective across India.

The manufacturing facility of Marck Biosciences, located near Ahmedabad, is spread over an area of 25 acres. The plant, equipment and systems have not only been designed to meet ISO Compliance and Good Manufacturing Practices but also meet the requirements of the regulatory authorities of advanced markets.